Details

Autor(en) / Beteiligte

• Bosserman, Rachel E.
• Farnsworth, Christopher W.
• O’Neil, Caroline A.
• Cass, Candice
• Park, Daniel
• Ballman, Claire
• Wallace, Meghan A.
• Struttmann, Emily
• Stewart, Henry
• Arter, Olivia
• Peacock, Kate
• Fraser, Victoria J.
• Budge, Philip J.
• Olsen, Margaret A.
• Burnham, Carey-Ann D.
• Babcock, Hilary M.
• Kwon, Jennie H.

Titel

Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021

Ist Teil von

• Antimicrobial stewardship & healthcare epidemiology : ASHE, 2023-01, Vol.3 (1), p.e133-e133, Article e133

Ort / Verlag

Cambridge: Cambridge University Press

Erscheinungsjahr

2023

Quelle

Elektronische Zeitschriftenbibliothek - Freely accessible e-journals

Beschreibungen/Notizen

• Abstract Objective: To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity. Design: Prospective cohort study. Setting: An academic, tertiary-care hospital in St. Louis, Missouri. Participants: The study included 400 HCP aged ≥18 years who potentially worked with coronavirus disease 2019 (COVID-19) patients and had no known history of COVID-19; 309 of these HCP also completed a follow-up visit 70–160 days after enrollment. Enrollment visits took place between September and December 2020. Follow-up visits took place between December 2020 and April 2021. Methods: At each study visit, participants underwent SARS-CoV-2 IgG N-antibody testing using the Abbott SARS-CoV-2 IgG assay and completed a survey providing information about demographics, job characteristics, comorbidities, symptoms, and potential SARS-CoV-2 exposures. Results: Participants were predominately women (64%) and white (79%), with median age of 34.5 years (interquartile range [IQR], 30–45). Among the 400 HCP, 18 (4.5%) were seropositive for IgG N-antibodies at enrollment. Also, 34 (11.0%) of 309 were seropositive at follow-up. HCP who reported having a household contact with COVID-19 had greater likelihood of seropositivity at both enrollment and at follow-up. Conclusions: In this cohort of HCP during the first wave of the COVID-19 pandemic, ∼1 in 20 had serological evidence of prior, undocumented SARS-CoV-2 infection at enrollment. Having a household contact with COVID-19 was associated with seropositivity.